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The objective of this study was to investigate whether differences in diet and in single-nucleotide 
polymorphisms (SNPs) found in paraoxonase-1 (PON-1), 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase (HMGCR), cholesterol ester transfer protein (CETP) and apolipoprotein E (APOE) genes, 
are associated with oxidative stress biomarkers and consequently with susceptibility of low-density 
cholesterol (LDL) to oxidation. A multivariate approach was applied to a group of 55 patients 
according to three biomarkers: plasma antioxidant activity, malondialdehyde and oxidized LDL 
(oxLDL) concentrations. Individuals classified in Cluster III showed the worst prognoses in terms 
of antioxidant activity and oxidative status. Individuals classified in Cluster I presented the lowest 
oxidative status, while individuals grouped in Cluster II presented the highest levels of antioxidant 
activity. No difference in nutrient intake was observed among the clusters. Significantly higher γ- and 
δ-tocopherol concentrations were observed in those individuals with the highest levels of antioxidant 
activity. No single linear regression was statistically significant, suggesting that mutant alleles of the 
SNPs selected did not contribute to the differences observed in oxidative stress response. Although 
not statistically significant, the p value of the APO E coefficient for oxLDL response was 0.096, 
indicating that patients who carry the TT allele of the APO E gene tend to present lower plasma oxLDL 
concentrations. Therefore, the differences in oxidative stress levels observed in this study could not 
be attributed to diet or to the variant alleles of PON-1, CETP, HMGCR or APO E. This data supports 
the influence of γ-tocopherol and δ-tocopherol on antioxidant activity, and highlights the need for 
further studies investigating APO E alleles and LDL oxidation.
Uniterms: Diet. Oxidative stress/biomarkers. Single-nucleotide polymorphism (SNPs). Lipoproteins/
oxidation. Statins. Apolipoprotein E.
O objetivo deste estudo foi investigar se diferenças na dieta e em polimorfismos de nucleotídeos únicos 
(SNPs) encontrados no gene da paraoxonase 1 (PON-1), da 3-hidroxi-3-metilglutaril-coenzima A 
reductase (HMGCR), da proteína de transferência de ésteres de colesterol (CETP) e da apolipoproteina 
E (APOE) estariam associadas com biomarcadores do estresse oxidativo e, consequentemente, com a 
suscetibilidade da LDL à oxidação. Técnicas da estatística multivariada foram aplicadas a um grupo de 55 
pacientes usando 3 biomarcadores: atividade antioxidante plasmática, concentrações de malondialdeído 
e LDL oxidada. Indivíduos classificados no cluster III apresentaram um prognóstico negativo em termos 
de atividade antioxidante e estado oxidativo. Os indivíduos agrupados no cluster I apresentaram o mais 
baixo nível de estado oxidativo, enquanto que indivíduos no cluster II apresentaram os mais altos níveis 
de atividade antioxidante. Nenhuma diferença na ingestão de nutrientes foi observada entre os clusters. 
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Concentrações estatísticamente mais altas de γ- e δ-tocoferol foram observadas em indivíduos com mais 
altos níveis de atividade antioxidante. A regressão linear aplicada não foi estaticamente significativa, 
sugerindo que os alelos mutantes dos SNPs selecionados não contribuíram para as diferenças nos níveis 
de estresse oxidativo. Embora não tenha sido estatisticamente significativa, o valor da probabilidade 
associado ao coeficiente da relação entre ApoE e oxLDL foi de 0,096, indicando que pacientes que 
carregam o alelo TT da ApoE tendem a apresentar menores concentrações plasmáticas de LDL oxidada. 
Portanto, as diferenças no estresse oxidativo observadas em nosso estudo não puderam ser atribuídas 
à dieta e alelos variantes de PON-1, CETP, HMGCR ou ApoE. Nossos dados suportam a influência 
γ- tocoferol e δ-tocoferol na atividade antioxidante e reforçam a necessidade de mais pesquisas que 
investiguem a relação entre alelos da Apo E e a oxidação da LDL.
Unitermos: Dieta. Estresse oxidativo/biomarcadores. Polimorfismo de nucleotídeo único (SNPs). 
Lipoproteína/oxidação. Estatinas. Apolipoproteina E.
INTRODUCTION
Atherosclerosis is clinically defined as a subacute 
inflammation of the vessel wall, characterized by infiltra-
tion of macrophages and T cells in the artery wall (Libby 
et al., 2011) . It is widely accepted that the atherosclerotic 
process begins with LDL oxidation (Steinberg et al., 1989; 
Witztum and Steinberg, 2001). Apolipoprotein B and the 
lipid fraction of LDL, suffer oxidation due to excess reac-
tive species, contributing to oxidative stress (Kontush et 
al., 2003; Stephens et al., 2008). In fact, modification of 
LDL seems to be the key determinant of lipid uptake by 
macrophages (Parthasarathy et al., 2008). Thus, chronic 
elevation of both reactive species and LDL circulating in 
the arteries can strongly contribute to the progression of 
atherosclerosis. 
Several specific proteins have been linked to LDL 
concentration and its susceptibility to oxidation. The focus 
of this study was atherosclerosis and its correlation with 
oxidative stress in this specific population. Therefore, 
SNPs associated with genes that encode proteins involved 
with both processes, the amount of LDL and its suscepti-
bility to oxidation by reactive species, such as cholesterol 
ester transfer protein (CETP), 3-hydroxy-3-methylgl-
utaryl-coenzyme A reductase (HMGCR), paraoxonase 
isoform 1 (PON-1) and apolipoprotein E (ApoE) were 
selected. The transport of cholesterol esters from HDL 
to VLDL depends on CETP activity (Thompson et al., 
2008). Low CETP activity and concentrations have been 
associated with elevated HDL (Zee et al., 2002; Van Acker 
et al., 2008). Statins, which inhibit HMGCR, block the 
rate-limiting step in cholesterol synthesis, induce mRNA 
transcription for the LDL receptor (Morikawa et al., 2000), 
and up-regulate LDL binding sites (Li et al., 2003), thus 
reducing the risk of coronary artery disease by around 30% 
(Zee et al., 2002). HDL exerts its protective effects through 
a number of mechanisms, including cholesterol reverse 
transport, inhibition of LDL oxidation and reduction of the 
inflammatory response (Proudfoot et al., 2009). Plasma 
HDL, especially the small and dense HDL3, contains an-
tioxidant enzymes with diverse substrate specificity, such 
as PON-1, platelet-activating factor acetylhydrolase (PAF-
AH), lecithin-cholesterol acyltransferase (LCAT) and 
apolipoproteins that can delay or inactivate the formation 
of oxidized lipids in LDL. Apolipoprotein (ApoE) plays 
an important role in lipid metabolism, thus mediating the 
binding and uptake of lipoproteins, and influencing cho-
lesterol homeostasis (Mahley, 1988; Kolovou et al., 2009).
Gene-environment interactions may influence oxi-
dative stress, LDL oxidation and subsequent cardiovas-
cular disease (Stephens et al., 2008). Exogenous factors 
such as nutrient intake also affect LDL concentrations 
and oxidation susceptibility. From a nutrigenomic point 
of view, nutrients and bioactive food components can 
interfere with gene expression (Kauwell, 2005). From 
a nutrigenetic perspective, any change in the nucleotide 
sequence of genes that encode proteins associated with 
oxidative stress may explain individual variation in the 
response to the same stimulus, resulting in different risks 
for the development of diet-related diseases. Thus, a better 
understanding of nutrigenomic and nutrigenetic effects 
will allow medical professionals to further optimize diet 
according to individual genetic profile. 
According to Stephens et al. (2008), relatively few 
publications have examined the association between gene 
variants and biochemical markers of oxidative stress in 
vivo. In a previous study, Botelho et al. (2010) observed 
no correlation between oxidative stress, as measured by 
four biomarkers, and dietary intake in individuals with 
dyslipidaemia controlled by statins. In this study, we in-
vestigated whether there was difference in the proportion 
of certain single nucleotide polymorphisms (SNPs) related 
to the lipid metabolism genes among clusters containing 
individuals with different oxidative stress conditions. 
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MATERIALS AND METHODS
Chemicals
All reagents were purchased from Sigma Chemical 
Co. (St Louis, MO, USA), Merck (Darmstadt, Germany) 
or Invitrogen (Carlsbad, CA, USA). All of the reagents 
used in the experiments were of analytical grade. Aque-
ous solutions were prepared with ultra-pure Milli-Q water 
(Millipore Ind. Com. Ltd, São Paulo, Brazil). Organic 
solvents were of high performance liquid chromatography 
(HPLC) grade.
Subjects
Subjects were recruited from the patient data bank 
at the Dante Pazzanese Institute of Cardiology (São Paulo, 
Brazil). From the hospital database containing 1056 pa-
tients, 82 individuals, including both males and females, 
were recruited to participate in this study. Patients were 
included if they were between 30 and 80 years old, had a 
BMI (body mass index) of between 18.5 and 29.9 kg/m2, 
and had been taking statins (simvastatin or atorvastatin – 
3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors) at 
doses ranging from 10 to 80 mg/day for at least 6 months. 
Patients were excluded from the study if they were preg-
nant or breast-feeding; if they had diabetes, kidney disease, 
endocrine disease, liver disease or a personal history of 
myocardial infarction or stroke; or if they were taking 
hormone treatment for menopause. Of the 82 individuals 
initially recruited, 55 participated in the study. The remain-
ing 27 volunteers were dropped from the study because 
they did not have their blood collected on time. This study 
was conducted according to the guidelines laid down in 
the Declaration of Helsinki, and all procedures involving 
human patients were approved by the Ethics Committee 
of the Pharmaceutical Science Faculty and the Dante Paz-
zanese Institute of Cardiology. Written, informed consent 
was obtained from all patients.
Dietary intake
Dietary intake was assessed using a 3-day food regis-
ter repeated twice. This food register provided information 
such as the type and amount of food eaten throughout the 
day, over 6 days. The macro- and micronutrient contents of 
the daily food consumption of each patient were obtained 
by the Nutriquanti® software program. This software was 
based on information from the United States Department 
of Agriculture’s database. Thus, the 6-day average intake 
of macronutrients was assessed, including carbohydrates, 
proteins and lipids (total, saturated, monounsaturated and 
polyunsaturated fats and cholesterol), along with some mi-
cronutrients, such as iron, manganese, zinc and vitamin C.
Measurement of biochemical variables
Enzymatic colorimetric methods were used to 
determine total serum cholesterol (Liquiform Cat. 76, 
using cholesterol esterase, cholesterol oxidase and per-
oxidase), HDL-cholesterol (Cat. 13, using precipitation 
with phosphotungstic acid and MgCl2) and triacylglycerol 
(GPO-ANA, Cat. 59, using glycerol 3-phosphate oxidase) 
concentrations. LDL-cholesterol concentrations were 
estimated using the Friedewald formula (Friedwald et al. 
1972). 
Oxidized-LDL (oxLDL) measurement
A sandwich ELISA methodology was used to 
evaluate the plasma concentration of oxLDL by spec-
trophotometry using a microplate reader (Spectra Count 
Microplate Photometer, Packard Instruments Company, 
Downers Grove, IL, USA) as described by Faulin et al. 
(2008). A calibration curve was carried out on each plate, 
using oxLDL extracted from human plasma by FPLC 
(Fast Protein Liquid Chromatography) as a standard 
(0.625 – 20,000 µg/mL). The results were expressed as U/l, 
with 1 unit representing 1.0 g/L oxidized Apo B.
Plasma tocopherol concentration
Measurements of α-, γ- and δ-tocopherol were 
performed in plasma samples by high-performance liq-
uid chromatography (HPLC) according to the protocol 
described by Siluk et al. (2007). A standard curve was pre-
pared using 10 - 30 µg/mL of α-tocopherol, 0.02 - 4 µg/mL 
for γ-tocopherol and 0.01 - 1 µg/mL for δ-tocopherol. 
Calibration curves were calculated using working solu-
tions of a mixture of analytes, and results expressed as 
µg/mL. 
Total antioxidant activity
Total antioxidant activity in serum and plasma 
samples was measured using three assays: 2,2-diphenyl-
1-picrylhydrazyl radical (DPPH) assay, ferric-reducing 
ability power (FRAP) and oxygen-radical absorbance 
capacity (ORAC). The DPPH method was carried out 
as previously described by Chrzczanowicz et al. (2008), 
whereas FRAP was performed according to Benzie and 
Strain (1999). The ORAC assay was performed in plasma 
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samples according to Prior et al. (2003). A calibration 
curve was prepared using Trolox solution at concentrations 
ranging from 6.5 to 50 µmol/L for the lipophilic assay and 
6.5 to 100 µmol/L for the hydrophilic assay.
Plasma malondialdehyde (MDA) concentration
The MDA concentrations in the plasma samples 
were determined by reverse phase HPLC (Agilent Tech-
nologies 1200 series; Santa Clara, CA, USA) according 
to Cheng et al. (2008), using a thiobarbituric acid (TBA) 
derivatization. A standard curve was prepared using 
malondialdehyde tetrabutylammonium salt (MDA) at 
concentrations ranging from 0.5 to 5.0 µmol/L. Results 
were expressed as µmol/L of MDA. 
DNA isolation and genotyping
DNA was extracted from whole blood by the salt-
ing out method described by Miller et al. (1988). After 
extraction, DNA was visualized after electrophoresis 
through a 1% agarose gel, and the DNA concentration 
was measured using a Nanodrop 8000 spectrophotometer 
(Thermo Scientific, Waltham, MA, USA). Genotyping of 
selected SNPs [PON-1 584G→A (Gln192Arg); CETP Taq 
IB C→ T (rs708272); HMGCR 29 T→G (rs17238540) 
and ApoE –219G→T (rs405509)] was performed using 
allele-specific polymerase chain reaction (ASPCR) or the 
amplification refractory mutation system (ARMS) (New-
ton et al., 1989). Amplification products were detected via 
fluorescence resonance energy transfer (FRET) analysis 
according to Livak et al. (1995). 
Statistical analysis
Results were expressed as mean and pooled SD. 
Principal component analysis (PCA) was applied to clas-
sify the individuals (n=55) according to their oxidative 
conditions based upon their oxidative stress biomarkers. 
The data matrix for independent variables expressed in 
different units was prepared by adopting biomarkers as 
columns and individuals as rows. Tree-clustering analy-
sis was used to group individuals according to similarity 
based upon the five biomarkers of oxidative stress (DPPH, 
ORAC, FRAP, MDA and oxLDL). This analysis was based 
on Ward’s method and Euclidean distances. Main-effects 
ANOVA, followed by Tukey’s HSD post-hoc test, was 
used to evaluate the differences among the three gener-
ated clusters. Homogeneity of variances was checked 
by Hartley’s test. Polymorphisms, i.e., the allele variant 
versus wild type allele, were admitted as independent 
variables, and linear models were fitted to the following 
responses: 1st Principal Component (PC1), MDA and 
oxLDL. ANOVA was applied to evaluate the significance 
of the three models. P values < 0.05 were considered to 
indicate significance. Statistical analyses were performed 
using STATISTICA 7.1 software (Statsoft Inc., Tulsa, OK, 
USA) and MINITAB 15 (Minitab Inc., State College, PA, 
USA). 
RESULTS
In this study, in addition to tocopherol concentra-
tions, five oxidative biomarkers were also evaluated in this 
population: antioxidant activity (DPPH, FRAP, ORAC), 
MDA and oxLDL (Table I). Significant linear correlations 
were observed between antioxidant activity in plasma 
measured by ORAC and FRAP (r = + 0.57, p < 0.001) 
and by ORAC and DPPH (+ 0.43, p = 0.001). Notably, 
the ORAC assay was performed one year after the FRAP 
and DPPH measurements were taken. Thus, our results 
suggest that, at least for comparison purposes, ORAC can 
be used to evaluate plasma samples stored at -80 °C for 
long periods of time. 
Multivariate analysis was performed using five 
oxidative biomarkers as active variables (ORAC, DPPH, 
FRAP, oxLDL and MDA). Cluster analysis was applied 
to classify the individuals (n=55) based on these five bio-
markers of oxidative stress. This analysis suggested that 
patients could be classified into three groups (clusters). 
Afterward, the other variables measured in this study were 
TABLE I - Oxidative stress biomarkers of subjects (n=55)
Variables Mean Values SD
MDA (µmo/L) 1.40 0.36
FRAP (µmol/L) 885.00 177
DPPH (% of inhibition) 4.5 1.3
oxLDL (U/L) 19.61 20.24
ORAC (hydro)(µmol TE/L) 1,704.36 292.59
ORAC (lipo)(µmol TE/L) 428.18 108.12
ORAC (total)(µmol TE/L) 2,118.00 311.98
α-tocopherol (µg/mL) 11.28 2.49
γ-tocopherol (µg/mL) 1.23 0.55
δ-tocopherol (µg/mL) 0.11 0.08
MDA malondialdehyde ; FRAP Ferric Reducing Anti-oxidant 
Power; DPPH 2.2-diphenyl-1-picrylhydrazyl radical; oxLDL 
oxidized low density lipoprotein; ORAC oxygen radical 
absorbance capacity
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FIGURE 1- Projection of the variables (oxidative stress 
biomarkers) on the factor-plane (1 x 2).
compared among the clusters. Projection of these groups 
onto the factor-plane (1 x 2) was performed by submit-
ting the matrix of data to Principal Component Analysis 
(PCA) (Figure 1). 
The contribution of each variable to the principal 
components (Table II) showed that antioxidant activity 
was responsible for the separation of individuals in the first 
principal component (PC1); oxLDL separated individuals 
in the second component (PC2), whereas MDA was well 
represented in the third component (PC3). 
Characterization of the three clusters according to 
nutrient intake, blood biochemistry and PON-1, HMGCR, 
CETP and ApoE polymorphisms is shown in Figure 2. 
No difference in nutrient intake between the clusters was 
observed (p<0.05). Although the patients showed a large 
age range, no significant correlations were observed be-
tween subjects’ age, oxidative biomarkers and nutrient 
intake. For this reason, Figure 2 was designed to show 
that individuals with the same nutrient intake exhibited 
differences in oxidative stress biomarkers.
The dietary intake values in Figure 2 represent the 
average intake of the 55 subjects. Individuals in Cluster III 
showed the worst prognoses in terms of antioxidant activ-
ity and oxidative status. Cluster I contained individuals 
with intermediate antioxidant activity, while individuals 
in Cluster II showed the highest antioxidant activity. No 
differences in plasma lipoprotein concentrations were 
observed between the clusters. However, the highest 
plasma γ-tocopherol and δ-tocopherol concentrations were 
observed in individuals who also exhibited the highest 
antioxidant activity (Cluster II).
The allelic distributions of all four polymorphisms 
characterized in this study were evaluated by the Chi-
square test and were in Hardy-Weinberg equilibrium. 
Tables III, IV and V depict the effects caused by each 
polymorphism on mean PC1, MDA and oxLDL responses, 
respectively. PC1 includes measurements for ORAC, 
DPPH and FRAP, representing an “antioxidant capacity” 
response. No linear regression model indicated a statisti-
cally significant effect for a particular polymorphism, 
and all coefficients had p-values higher than 0.05. The 
calculated determination coefficients (R2) were also low 
(<12%), indicating that the mutant alleles could not ex-
plain the variation in these results. Although no statistical 
significance was observed, the p-value of the ApoE coef-
ficient in the oxLDL response was 0.096, suggesting that 
patients carrying the TT allele in the ApoE gene tend to 
exhibit reduced plasma oxLDL concentrations.
DISCUSSION
The individuals with statin-controlled dyslipidaemia 
presented different profiles of total antioxidant activity 
(PC1) and oxidative status (MDA and oxLDL), but these 
differences could not be associated with their nutrient 
intake, plasma lipoprotein concentration or polymor-
phisms in CETP, HMGCR, PON-1 and ApoE proteins. 
The CETP, HMGCR and ApoE polymorphisms were 
selected in this study due to their strong association with 
lipoprotein metabolism and increased availability of LDL 
as a substrate for oxidation. For example, a reduction in 
CETP activity implies an increase in HDL, reducing the 
risk of LDL for oxidation. Among the SNPs investigated 
in this study, PON-1 (584G→A) appears to be the most 
TABLE II - Factor coordinates of variables, based on correlations
Variables PC 1 PC 2 PC 3
ORAC -0.76 0.19 0.15
MDA 0.08 0.54 -0.84
FRAP -0.91 0.04 -0.01
DPPH -0.86 -0.10 -0.16
oxLDL 0.06 0.85 0.48
PC principal component; MDA malondialdehyde ; FRAP 
Ferric Reducing Antioxidant Power; DPPH 2.2-diphenyl-1-
picrylhydrazyl radical; oxLDL oxidized low density lipoprotein; 
ORAC oxygen radical absorbance capacity
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FIGURE 2 - Classification of studied individuals (n=55) according to cluster analysis and characterization of the three clusters based 
on nutrient intake, blood biochemistry and polymorphisms in PON-1, HMGCR, CETP and APO E genes. SAFA - saturated fatty 
acids; MUFA - monounsaturated fatty acids; PUFA - polyunsaturated fatty acids; ORAC - oxygen radical absorbance capacity; 
FRAP - ferric-reducing antioxidant power; DPPH - 2,2-diphenyl-1-picrylhydrazyl radical; MDA - malondialdehyde; oxLDL - 
oxidized low density lipoprotein; HDL - high density lipoprotein; PON1 - paraoxonase 1; HMGCR - 3-hydroxy-3-methylglutaryl-
coenzyme A reductase; CETP - cholesterol ester transfer protein; ApoE - apolipoprotein E; M - mutant gene; WT – wild-type. P 
values obtained by ANOVA: α-tocopherol (p=0.316), γ-tocopherol (p=0.006), δ-tocopherol (p=0.003), ORAC (p=0.001), FRAP 
(p <0.001), DPPH (p= 0.004), MDA (p=0.052), oxLDL (p=0.145) and CHOL nHDL (p=0.208). Means for the same variable with 
different superscript letters are significantly different, p<0.05.
TABLE III - Coefficients of the linear models adjusted to Principal 
Component 1 response (antioxidant activity response)
Predictor Coefficient SE P value
Constant 0.2019 0.5256 0.703
PON1 -0.2275 0.4571 0.621
CETP 0.3768 0.4843 0.441
HMGCR -0.7173 0.9230 0.441
ApoE -0.3687 0.4677 0.435
PON 1 Paraoxonase 1 ; CETP Cholesteryl Ester Transfer 
Protein; HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase ; ApoE Apolipoprotein E ; SE Standard Error
TABLE IV - Coefficients of the linear models adjusted to oxLDL 
response
Predictor Coefficient SE P value
Constant 41,925.0 7,494.0 0.000
PON1 -3,755.0 6,518.0 0.568
CETP -4,932.0 6,905.0 0.479
HMGCR -13,689.0 13,161.0 0.304
ApoE -11,373.0 6,669.0 0.096
PON 1 Paraoxonase 1 ; CETP Cholesteryl Ester Transfer 
Protein; HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase ; ApoE Apolipoprotein E ; SE Standard Error
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relevant because the PON-1 enzyme protects lipoproteins 
against oxidative stress by metabolizing lipid peroxides. In 
addition, the significant differences between biomarkers 
across clusters could be interpreted as a lack of adaptive 
response to oxidative stress of these individuals (Crawford 
and Davies, 1994), such as increased activity or expression 
of antioxidant enzymes.
This study demonstrated the advantages of using a 
multivariate statistical approach to investigate associations 
between polymorphisms and oxidative stress. Firstly, many 
responses can be grouped by multivariate techniques into 
principal components. Secondly, it is possible to measure 
the direct effects of wild-type and mutant alleles on these 
responses or on the principal components. A third advan-
tage of this statistical treatment is that interactions among 
polymorphisms can be identified and discussed. The lack of 
significance of those models including polymorphisms and 
oxidative response observed in this study may be attributed 
to the low number of individuals in each genetic subgroup. 
According to Kajinami et al. (2004), generating a sample 
size large enough for adequate statistics is a key issue for 
pharmacogenetic studies, and this situation may also apply 
to nutrigenetics research. Although the number of patients 
included in this study is considered low, it was sufficient to 
demonstrate how multivariate techniques can be applied 
to classify individuals according to several parameters and 
then to determine differences in the proportion of SNPs 
among the groups formed. This is the first time that the 
procedure has been used to evaluate the presence of poly-
morphisms in patients before their classification according 
to susceptibility to oxidation.
However, a real absence of association between the 
selected SNPs and the oxidative biomarkers cannot be ex-
cluded. CETP concentration is associated with the common 
Taq 1B polymorphism, and carriers of the B2 allele exhibit 
lower plasma CETP levels, higher HDL and reduced risk for 
coronary heart disease (Boekholdt et al., 2005; Thompson 
et al., 2008; Van Acker et al., 2008). However, other studies 
of different CETP polymorphisms, such as -629 C>A and 
Taq IB, did not support this association (Lu et al., 2003; 
Tanrikulu et al., 2009). Overall, the influence of CETP on 
the anti-atherogenic properties of HDL in vivo must be 
investigated. Individuals who are heterozygous for the G 
allele of rs17238540 at the HMGCR gene may respond 
less well to statin therapy in terms of total cholesterol and 
triglyceride levels (Chasman et al., 2004; Donelly et al., 
2008). The majority of individuals evaluated in the present 
study were wild-type allele carriers. Therefore, the influence 
of the mutant allele could not be evaluated here. 
Paraoxonase isoform 1 (PON-1) is a glycoprotein 
expressed primarily in the liver and contributes to HDL 
antioxidant activity (Bhattacharyya et al., 2008; Rainwater 
et al., 2009). PON-1 is able to delay LDL oxidation by 
hydrolyzing oxidized phospholipids and hydroperoxides, 
playing an anti-atherogenic role (Ng et al., 2005). The 
Q192R SNP (rs662) in the PON-1 gene replaces a gluta-
mine residue with an arginine residue at position 192 in 
the amino acid chain. This substitution can influence the 
lipoperoxide hydrolyzing activity of PON-1 and its anti-
oxidant activity, where this polymorphism is associated 
with coronary artery disease, stroke and familial hyper-
cholesterolemia (Ng et al., 2005). However, Robertson et 
al. (2003) suggested that the PON-1 polymorphisms may 
have little or no effect on CVD risk in healthy subjects 
unless other factors, such as diabetes, are present.
Our results showed a tendency (p=0.096) of the 
ApoE allele (T) to reduce oxLDL concentration. Compari-
son of the linear regression coefficients with the cluster 
analysis suggests that this result may be associated with 
the homozygous condition (TT). Lambert et al. (2000) 
reported that the -219T allele of ApoE (also called Th1/
E47cs) was associated with a significant reduction in myo-
cardial infarction. This effect was shown be independent 
of the presence of other Apo E mutations, including the ε2/
ε3/ε4 polymorphisms (Ye et al., 2003). Viiri et al. ( 2005) 
observed that the more common -219G genotype (G) was 
found more frequently in a group with high plasma VLDL, 
ApoE and triacylglycerol concentrations and was associ-
ated with lower plasma HDL concentrations. Viitanen et 
al. (2001) demonstrated that the -219T allele tended to 
influence total or LDL cholesterol levels and was related 
to atherosclerosis in coronary arteries. 
This analysis revealed a significant association 
between high γ-tocopherol and δ-tocopherol plasma 
concentrations and the highest antioxidant activity. Sev-
eral studies have investigated the effects of α-tocopherol 
supplementation on oxidative biomarkers. Although an 
inverse correlation has been observed between elevated 
TABLE V - Coefficients of the linear models adjusted to MDA 
response
Predictor Coefficient SE P value
Constant 1.2257 0.1019 0.000
PON1 0.0852 0.0886 0.341
CETP 0.0916 0.0939 0.335
HMGCR 0.1877 0.1789 0.300
ApoE 0.1081 0.0906 0.240
PON 1 Paraoxonase 1 ; CETP Cholesteryl Ester Transfer 
Protein; HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase ; ApoE Apolipoprotein E ; SE Standard Error
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α-tocopherol plasma levels and decreased oxidation bio-
markers, no practical effects of α-tocopherol status and 
cardiovascular events have been demonstrated (Vive-
kananthan et al., 2003; Roberts et al., 2007). According 
to Devarej et al. (2008), γ-tocopherol supplementation 
alone significantly reduces biomarkers of oxidative stress, 
plasma MDA and lipid peroxides, and is more potent than 
α-tocopherol for decreasing nitrosative stress. After a 
thorough review of the effect of tocopherols on heart dis-
ease, Jialal and Devaraj (2005) recommended that serious 
consideration should be given to the use of γ-tocopherol 
supplementation to reduce biomarkers of oxidative stress.
CONCLUSION
In conclusion, this study presents a new statistical 
approach to evaluating polymorphisms and oxidative 
biomarkers in humans. Based on the data presented, differ-
ences in oxidative status between the individuals selected 
in the study cannot be attributed to diet or lipoprotein 
profile changes nor to the presence of SNPs in the PON-1, 
CETP, HMGCR and ApoE genes involved in lipoprotein 
metabolism. However, the study results corroborate the 
influence of γ-tocopherol and δ-tocopherol on antioxi-
dant activity in humans and reinforce the need for further 
research investigating APO E alleles and LDL oxidation.
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